<p>AngioDynamics（纳斯达克：ANGO - 获取免费报告）预计将在 2026 年 1 月 6 日星期二市场开盘前发布其 2026 财年第二季度业绩。分析师预计 AngioDynamics 每股收益为（$0.10），季度收入为 7643.30 万美元。AngioDynamics 已将其 2026 财年的指导目标设定为每股收益-0.330 至-0.230。个人可以访问公司即将发布的 2026 财年第二季度业绩页面，以获取有关定于 2026 年 1 月 6 日东部时间上午 8:00 的电话会议的最新信息。</p>
<p>获取 <strong>AngioDynamics</strong> 警报：</p>
<p>AngioDynamics（纳斯达克：ANGO - 获取免费报告）最近在 2023 年 10 月 2 日星期四发布了其财报。这家医疗器械供应商报告的季度每股收益为（$0.10），超出分析师共识预期的（$0.12）$0.02。该公司在本季度的收入为 7571 万美元，而分析师预期为 7269 万美元。AngioDynamics 的股本回报率为-3.16%，净利润率为-10.67%。与去年同期相比，AngioDynamics 的收入增长了 12.1%。在去年同期，该公司每股收益为（$0.11）。分析师平均预计 AngioDynamics 在当前财年和下一个财年每股收益均为$0。</p>
<h2>AngioDynamics 价格表现</h2>
<p>ANGO 股票在星期二开盘价为$12.87。该公司的 50 日移动平均线为$12.61，200 日移动平均线为$10.91。该公司的市值为 5.3024 亿美元，市盈率为-16.50，贝塔值为 0.49。AngioDynamics 的 1 年最低价为$8.27，1 年最高价为$13.99。</p>
<h2>内部交易活动</h2>
<p>在其他新闻中，首席执行官 James C. Clemmer 在 2023 年 10 月 9 日星期四购买了 10,000 股公司的股票，交易价格为每股$11.15，总价值为$111,500.00。交易完成后，首席执行官直接持有 882,529 股公司股票，价值约为$9,840,198.35。这代表其持股比例增加了 1.15%。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，高级副总裁 Lawrence T. Weiss 在 2023 年 10 月 21 日星期二购买了 10,000 股股票，交易价格为每股$11.81，总交易额为$118,100.00。交易完成后，该高级副总裁持有 93,597 股公司股票，价值约为$1,105,380.57。该交易使其持股比例增加了 11.96%。有关此购买的更多详细信息可在官方 SEC 披露中找到。在过去的九十天里，内部人士购买了价值$239,532 的 20,890 股公司股票。公司内部人士持有 6.00% 的公司股票。</p>
<h2>机构投资者对 AngioDynamics 的看法</h2>
<p>一些机构投资者和对冲基金最近对 ANGO 的持仓进行了调整。怀俄明州购买了 AngioDynamics 的新股份，价值约为$31,000。拉塞尔投资集团在第三季度将其在 AngioDynamics 的持仓增加了 329.5%。拉塞尔投资集团现在拥有 4,188 股医疗器械供应商的股票，价值$47,000，此前在上个季度又购买了 3,213 股。塔楼研究资本公司在第二季度将其在 AngioDynamics 的持仓增加了 359.0%。塔楼研究资本公司现在拥有 5,457 股医疗器械供应商的股票，价值$54,000，此前在此期间又购买了 4,268 股。法国巴黎银行金融市场在第三季度将其在 AngioDynamics 的持仓增加了 106.0%。法国巴黎银行金融市场现在拥有 7,473 股医疗器械供应商的股票，价值$83,000，此前在上个季度又购买了 3,846 股。最后，雷蒙德·詹姆斯金融公司在第二季度购买了 AngioDynamics 的新股份，价值约为$90,000。89.43% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>一些股票研究分析师对该股票发表了评论。Weiss Ratings 在 2023 年 10 月 8 日的研究报告中重新发布了对 AngioDynamics 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 在 2023 年 10 月 3 日的报告中将 AngioDynamics 的目标价格从$17.00 提高到$18.00，并给予该公司 “买入” 评级。最后，华尔街 Zen 在 2023 年 12 月 21 日的研究报告中将 AngioDynamics 的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为$19.33。</p>
<p><strong>查看我们对 AngioDynamics 的最新分析</strong></p>
<h2>AngioDynamics 公司简介</h2>
<p>（获取免费报告）</p>
<p>AngioDynamics, Inc 是一家总部位于纽约拉瑟姆的医疗技术公司，开发、制造和销售一系列微创医疗设备。公司的产品专注于三个核心领域：血管通路、外周血管介入和介入肿瘤学。其解决方案旨在改善手术结果，减少并发症，并提高医院和门诊环境中的患者舒适度。</p>
<p>在血管通路领域，AngioDynamics 提供一系列设备，包括植入式端口、外周插入中心导管（PICCs）、血液透析导管和特殊血液管理产品。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票超过 AngioDynamics</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>在美国鬼城发现的$100 万亿 “人工智能金属”</li>
<li>现在抛售这五只股票！</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能飙升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 AngioDynamics 吗？</h2>
<p>在考虑 AngioDynamics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AngioDynamics 并不在名单上。</p>
<p>虽然 AngioDynamics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿吉奥动态

<p>AngioDynamics（纳斯达克代码：ANGO）将于 1 月 6 日发布 2026 财年第二季度财报，分析师预计每股亏损 0.10 美元，收入为 7643 万美元。该公司已提供 2026 财年的指导，预计每股收益在-0.330 到-0.230 之间。最近的内部交易包括首席执行官 James C. Clemmer 购买了 10,000 股。机构投资者也增加了对 AngioDynamics 的持股，89.43% 的股票由对冲基金持有。分析师的评级各异，普遍共识为 “适度买入”</p>

<p>AngioDynamics (NASDAQ:ANGO - Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect AngioDynamics to post earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. Individuals may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>AngioDynamics（纳斯达克：ANGO - 获取免费报告）预计将在 2026 年 1 月 6 日星期二市场开盘前发布其 2026 财年第二季度业绩。分析师预计 AngioDynamics 每股收益为（$0.10），季度收入为 7643.30 万美元。AngioDynamics 已将其 2026 财年的指导目标设定为每股收益-0.330 至-0.230。个人可以访问公司即将发布的 2026 财年第二季度业绩页面，以获取有关定于 2026 年 1 月 6 日东部时间上午 8:00 的电话会议的最新信息。</p>
</div><p>Get <strong>AngioDynamics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>AngioDynamics</strong> 警报：</p>
</div><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The firm had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics's revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>AngioDynamics（纳斯达克：ANGO - 获取免费报告）最近在 2023 年 10 月 2 日星期四发布了其财报。这家医疗器械供应商报告的季度每股收益为（$0.10），超出分析师共识预期的（$0.12）$0.02。该公司在本季度的收入为 7571 万美元，而分析师预期为 7269 万美元。AngioDynamics 的股本回报率为-3.16%，净利润率为-10.67%。与去年同期相比，AngioDynamics 的收入增长了 12.1%。在去年同期，该公司每股收益为（$0.11）。分析师平均预计 AngioDynamics 在当前财年和下一个财年每股收益均为$0。</p>
</div><h2>AngioDynamics Price Performance</h2>
<div class="lb-trans"><h2>AngioDynamics 价格表现</h2>
</div><p>ANGO stock opened at $12.87 on Tuesday. The business's 50-day moving average is $12.61 and its two-hundred day moving average is $10.91. The firm has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49. AngioDynamics has a 1 year low of $8.27 and a 1 year high of $13.99.</p>
<div class="lb-trans"><p>ANGO 股票在星期二开盘价为$12.87。该公司的 50 日移动平均线为$12.61，200 日移动平均线为$10.91。该公司的市值为 5.3024 亿美元，市盈率为-16.50，贝塔值为 0.49。AngioDynamics 的 1 年最低价为$8.27，1 年最高价为$13.99。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CEO James C. Clemmer purchased 10,000 shares of the business's stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president owned 93,597 shares of the company's stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 20,890 shares of company stock worth $239,532. Corporate insiders own 6.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 James C. Clemmer 在 2023 年 10 月 9 日星期四购买了 10,000 股公司的股票，交易价格为每股$11.15，总价值为$111,500.00。交易完成后，首席执行官直接持有 882,529 股公司股票，价值约为$9,840,198.35。这代表其持股比例增加了 1.15%。该购买在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，高级副总裁 Lawrence T. Weiss 在 2023 年 10 月 21 日星期二购买了 10,000 股股票，交易价格为每股$11.81，总交易额为$118,100.00。交易完成后，该高级副总裁持有 93,597 股公司股票，价值约为$1,105,380.57。该交易使其持股比例增加了 11.96%。有关此购买的更多详细信息可在官方 SEC 披露中找到。在过去的九十天里，内部人士购买了价值$239,532 的 20,890 股公司股票。公司内部人士持有 6.00% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On AngioDynamics</h2>
<div class="lb-trans"><h2>机构投资者对 AngioDynamics 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in ANGO. State of Wyoming purchased a new stake in shares of AngioDynamics in the second quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its position in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 4,268 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of AngioDynamics by 106.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier's stock valued at $83,000 after purchasing an additional 3,846 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of AngioDynamics in the 2nd quarter valued at about $90,000. 89.43% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 ANGO 的持仓进行了调整。怀俄明州购买了 AngioDynamics 的新股份，价值约为$31,000。拉塞尔投资集团在第三季度将其在 AngioDynamics 的持仓增加了 329.5%。拉塞尔投资集团现在拥有 4,188 股医疗器械供应商的股票，价值$47,000，此前在上个季度又购买了 3,213 股。塔楼研究资本公司在第二季度将其在 AngioDynamics 的持仓增加了 359.0%。塔楼研究资本公司现在拥有 5,457 股医疗器械供应商的股票，价值$54,000，此前在此期间又购买了 4,268 股。法国巴黎银行金融市场在第三季度将其在 AngioDynamics 的持仓增加了 106.0%。法国巴黎银行金融市场现在拥有 7,473 股医疗器械供应商的股票，价值$83,000，此前在上个季度又购买了 3,846 股。最后，雷蒙德·詹姆斯金融公司在第二季度购买了 AngioDynamics 的新股份，价值约为$90,000。89.43% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of equities research analysts have commented on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their target price on AngioDynamics from $17.00 to $18.00 and gave the company a &#34;buy&#34; rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut AngioDynamics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $19.33.</p>
<div class="lb-trans"><p>一些股票研究分析师对该股票发表了评论。Weiss Ratings 在 2023 年 10 月 8 日的研究报告中重新发布了对 AngioDynamics 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 在 2023 年 10 月 3 日的报告中将 AngioDynamics 的目标价格从$17.00 提高到$18.00，并给予该公司 “买入” 评级。最后，华尔街 Zen 在 2023 年 12 月 21 日的研究报告中将 AngioDynamics 的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为$19.33。</p>
</div><p><strong>Check Out Our Latest Analysis on AngioDynamics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AngioDynamics 的最新分析</strong></p>
</div><h2>AngioDynamics Company Profile</h2>
<div class="lb-trans"><h2>AngioDynamics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.</p>
<div class="lb-trans"><p>AngioDynamics, Inc 是一家总部位于纽约拉瑟姆的医疗技术公司，开发、制造和销售一系列微创医疗设备。公司的产品专注于三个核心领域：血管通路、外周血管介入和介入肿瘤学。其解决方案旨在改善手术结果，减少并发症，并提高医院和门诊环境中的患者舒适度。</p>
</div><p>In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.</p>
<div class="lb-trans"><p>在血管通路领域，AngioDynamics 提供一系列设备，包括植入式端口、外周插入中心导管（PICCs）、血液透析导管和特殊血液管理产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than AngioDynamics</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>$100 Trillion “AI Metal” Found in American Ghost Town</li>
<li>Drop these 5 stocks now!</li>
<li>Trump’s new AI budget just passed — one stock could soar</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 AngioDynamics</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>在美国鬼城发现的$100 万亿 “人工智能金属”</li>
<li>现在抛售这五只股票！</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能飙升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANGO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AngioDynamics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 AngioDynamics 吗？</h2>
</div><p>Before you consider AngioDynamics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AngioDynamics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AngioDynamics 并不在名单上。</p>
</div><p>While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AngioDynamics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Angiodynamics（ANGO）将于周二公布财报